Using the LGR5 Protein as a Biomarker in Thyroid Cancer

November 7, 2014
Brittany N. Bohinc, MD

Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.

Clinical Pearls

Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.

  • LGR5 is a protein that marks cancer stems cells. It is known to be important in colorectal cancer and gastric cancer.
  • Using two methods, researchers found that LGR5 was highly expressed in papillary thyroid cancer.
  • LGR5 in thyroid cancer is associated with lymph node number, lymph node metastases, tumor size, T stage, N stage, extrathyroidal extension, lymphovascular invasion, and macroscopic extension.
  • LGR5 could be used as a biomarker for novel therapeutics or risk stratification for surgery.